You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
艾德生物(300685.SZ):自研伴隨診斷產品將用於Pierre Fabre的BRAF抑制劑Encorafenib和Binimetinib在非小細胞肺癌及Encorafenib在腸癌領域中國的伴隨診斷註冊
格隆匯 02-24 16:16

格隆匯2月24日丨艾德生物(300685.SZ)公佈,近日,公司與INSTITUT DE RECHERCHE PIERRE FABRE(簡稱“PierreFabre”)簽署了合作協議。公司自主研發的伴隨診斷產品將用於Pierre Fabre的BRAF抑制劑Encorafenib和Binimetinib在非小細胞肺癌及Encorafenib在腸癌領域中國的伴隨診斷註冊。

Pierre Fabre是法國的私營製藥集團,在腫瘤學的創新、開發、製造和商業化方面擁有多年的經驗。集團擁有多個醫療特許經營權和國際品牌,其中包括:皮爾法伯腫瘤學研究、皮爾法伯皮膚學研究等。

Encorafenib聯合Binimetinib在歐盟獲批治療攜帶BRAF V600突變的不可手術切除或已轉移的黑色素瘤患者,Encorafenib還適用於與西妥昔單抗聯合治療具有BRAF V600E突變,且接受過系統性治療的轉移性結直腸癌成人患者。Encorafenib和Binimetinib尚未在中國註冊。Pierre Fabre擁有Encorafenib和Binimetinib在歐洲和亞洲(除韓國、日本外)地區的商業化權益。

公司表示,此次Pierre Fabre選擇公司作為非小細胞肺癌及腸癌中國臨牀的BRAF伴隨診斷合作伙伴,是對艾德品牌和產品的信任和肯定,有利於進一步增強公司在腫瘤精準醫療市場的競爭力,對公司未來的發展將產生積極影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account